Life Sciences

This issue of Vital Signs, released on June 2, 2014, discusses the latest strategy surrounding mega deals in the pharma/biotech industry, Eurofins agreement to acquire ViroCor-IBT Laboratories, Qiagens acquisition of BIOBASE, and the FDAs latest announcement on regulatory requirements for biosimilars.

This issue of Vital Signs, released on May 1, 2014, discusses the mega deals brewing in the pharma/biotech industry, Pfizer Incs Xalkori for non-small cell lung cancer, Novartis halt on RNAi development efforts, the high-ranked Malaysian healthcare system, Roches acquisition of IQuums Liat Analyzer, and Bio-Rads acquisition of GnuBio.

In 2013, healthcare moved towards access, transparency,  investments, and spending. In 2014, Frost & Sullivan anticipates new launches to occur across the life sciences spectrum, from preventive medicine to treating complex diseases. This market insight touches upon major events that occurred in 2013 and how 2014 is expected to shape up, includi...

Prescription drug therapy for the treatment of obesity is experiencing a revival of interest with new government incentives and the recent approval of 2 new drugs, with 2 more pending imminent approval. This research service focuses on the competitive landscape of prescription drugs for the treatment of obesity. A global product and pipeline asse...

While there is a positive outlook for global in vitro diagnostics (IVD), top companies face challenges such as slowing growth, increasing competition, and a changing business environment. This market insight will analyze the current healthcare reality and effective strategies in 2014 and beyond. The study will examine high-growth IVD segments and t...

The future of healthcare is moving towards become more personalized. An individuals genetic information is become a crucial component to assess the risks and predispositions one has towards acquiring a while host of indications. Embracing genetic best tests, will help world economies by reducing the millions of dollars spent in present diagnostic a...

Immunoglobulin therapies are life-saving medicines that have been in use for more than 60 years. They provide the patient with a variety of antibodies and are often used as a last line of defense in many severe inflammatory diseases. In some conditions, they are life-saving. However, immunoglobulin therapies are expensive. Despite this, global dem...

The dermatology space has been transformed with the introduction of biologic therapy for psoriasis, with several additional novel drug classes on the verge of market introduction. This research service provides a comprehensive overview and analysis of marketed and investigational products for the treatment of psoriasis. Information on market backg...